Latrepirdine (Dimebon TM) was originally marketed as a non-selective antihistamine in
Russia. It was repurposed as an effective treatment for patients suffering from Alzheimer's …

Dimebon (latrepirdine) is an anti-histaminergic agent which belongs to a fast-growing group
of “old” medicines suggested to be of therapeutic utility for pathological conditions different …

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with
ubiquitinated inclusions (FTLD-U) are major neurodegenerative diseases with TDP-43 …

Latrepirdine (Dimebon™), an anti-histamine, has shown some benefits in trials of
neurodegenerative diseases characterized by accumulation of aggregated or misfolded …

A number of neurodegenerative disorders were recently coalesced into a group of
proteinopathies based on the similarity of molecular mechanisms underlying their …

Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new
therapeutic properties were rediscovered, adding to a growing body of “old” agents with …

A synthetic approach to the design of new multitarget neuroprotectors consisting in
combination of the tetrahydrocarbazole and aminoadamantane pharmacophore fragments …

Uncontrolled protein aggregation, accompanied by the formation of specific inclusions, is a
major component of the pathogenesis of many common neurodegenerative diseases known …

Earlier unknown conjugates of carbazoles and γ-carbolines were obtained by the reaction of
3, 6-substituted 9-oxiranylmethylcarbazoles and 2, 8-substituted 2, 3, 4, 5-tetrahydro-1 H …

An approach for modification of biologically active N-substituted tetrahydro-γ-carbolines with
bis (dimethylamino) phenothiazine moiety via the CsF-catalyzed reaction of γ-carbolines …